Gynäkologische Tumoren

AGO-OVAR 28 /ENGOT-ov57

Status: aktiv
Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
Kurzinformation
Anprechpartner:
Axel Millahn
Telefon: 0711 278 53201
E-Mail: a.millahn@klinikum-stuttgart.de
Studienzentrale
Telefon: 0711 278 54961, -54539
E-Mail: scc-studienzentrale@klinikum-stuttgart.de

Status: aktiv
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
Kurzinformation
Anprechpartner:
Axel Millahn
Telefon: 0711 278 53201
E-Mail: a.millahn@klinikum-stuttgart.de
Studienzentrale
Telefon: 0711 278 54961, -54539
E-Mail: scc-studienzentrale@klinikum-stuttgart.de

Status: aktiv
Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer
Kurzinformation
Anprechpartner:
Axel Millahn
Telefon: 0711 278 53201
E-Mail: a.millahn@klinikum-stuttgart.de
Studienzentrale
Telefon: 0711 278 54961, -54539
E-Mail: scc-studienzentrale@klinikum-stuttgart.de

Status: aktiv
Prospektive, multizentrische Registerstudie zur Bewertung verschiedener leitlinienkonformer Operationsverfahren in der Axilla (Sentinel-Node Biopsie, Targeted Axillary Dissection, Axilladissektion) nach neoadjuvanter Chemotherapie
Kurzinformation
Anprechpartner:
Dr. med. Timo Basali
E-Mail: t.basali@klinikum-stuttgart.de
Studienzentrale
Telefon: 0711 278 54961, -54539
E-Mail: scc-studienzentrale@klinikum-stuttgart.de

Status: aktiv
Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes
Kurzinformation
Anprechpartner:
Axel Millahn
Telefon: 0711 278 53201
E-Mail: a.millahn@klinikum-stuttgart.de
Studienzentrale
Telefon: 0711 278 54961, -54539
E-Mail: scc-studienzentrale@klinikum-stuttgart.de

Status: in Vorbereitung
A non-interventional study for Kisqali (ribociclib) in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer at high risk of recurrence to evaluate real-world effectiveness, safety profile, patient compliance and quality of life (CAROLEEN)
Kurzinformation
Anprechpartner:
Axel Millahn
Telefon: 0711 278 53201
E-Mail: a.millahn@klinikum-stuttgart.de
Studienzentrale
Telefon: 0711 278 54961, -54539
E-Mail: scc-studienzentrale@klinikum-stuttgart.de